Compare ZDGE & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | XLO |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | ZDGE | XLO |
|---|---|---|
| Price | $2.52 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 57.6K | ★ 648.7K |
| Earning Date | 12-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $29,398,000.00 | ★ $31,804,000.00 |
| Revenue This Year | $2.37 | $589.60 |
| Revenue Next Year | $4.54 | $38.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $1.73 | $0.62 |
| 52 Week High | $4.89 | $1.70 |
| Indicator | ZDGE | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 43.26 |
| Support Level | $2.23 | $0.69 |
| Resistance Level | $2.47 | $0.75 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 56.13 | 30.90 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.